🇺🇸 FDA
Pipeline program

REGN727(SAR236553)

R727-CL-1001

Phase 1 small_molecule completed

Quick answer

REGN727(SAR236553) for Hypercholesterolemia is a Phase 1 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Hypercholesterolemia
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials